HIGHER MELPHALAN EXPOSURE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL FOR MYELOMA PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT

被引:6
|
作者
Shaw, P. J. [1 ,2 ]
Nath, C. E. [1 ]
Nivison-Smith, I [3 ]
Joshua, D. E. [2 ,4 ]
Kerridge, I. H. [2 ,5 ]
Presgrave, P. [6 ]
Tiley, C. R. [7 ]
Kwan, Y. L. [8 ]
Trotman, J. [2 ,8 ]
机构
[1] Childrens Hosp Westmead, Sydney, NSW, Australia
[2] Univ Sydney, Sydney, NSW 2006, Australia
[3] St Vincents Hosp, Sydney, NSW 2010, Australia
[4] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[5] Royal N Shore Hosp, Sydney, NSW, Australia
[6] Wollongong Hosp, Wollongong, NSW, Australia
[7] Gosford Hosp, Gosford, England
[8] Concord Hosp, Sydney, NSW, Australia
关键词
D O I
10.1016/j.bbmt.2011.12.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
13
引用
收藏
页码:S207 / S207
页数:1
相关论文
共 50 条
  • [21] Obesity is associated with higher overall survival in patients undergoing an outpatient reduced-intensity conditioning hematopoietic stem cell transplant
    Carlos Jaime-Perez, Jose
    Colunga-Pedraza, Perla R.
    Gutierrez-Gurrola, Balbina
    Brito-Ramirez, Alma S.
    Gutierrez-Aguirre, Homero
    Cantu-Rodriguez, Olga G.
    Luis Herrera-Garza, Jose
    Gomez-Almaguer, David
    BLOOD CELLS MOLECULES AND DISEASES, 2013, 51 (01) : 61 - 65
  • [22] Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant
    Sweiss, Karen
    Vemu, Bhaskar
    Calip, Gregory Sampang
    Galvin, John P.
    Quigley, John G.
    Mahmud, Nadim
    Rondelli, Damiano
    Johnson, Jeremy
    Patel, Pritesh
    BLOOD, 2019, 134
  • [23] Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation
    Ho, Christine M.
    Hahn, Theresa
    Wallace, Paul K.
    Zhang, Yali
    Fora, Ahmad
    Chen, George L.
    Holstein, Sarah A.
    Mellors, Patrick
    McCarthy, Benjamin
    Balderman, Sophia R.
    McCarthy, Philip L.
    BLOOD, 2016, 128 (22)
  • [24] Propylene Glycol-Free Melphalan May Induce Higher Remission Rates in Multiple Myeloma Patients Undergoing Autologous Transplantation
    Aljitawi, Omar
    Ludlow, Anna
    Ganguly, Siddhartha
    Abhyankar, Sunil
    Lin, Tara
    Pipkin, J. D.
    McGuirk, Joseph P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S178 - S178
  • [25] Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation
    Gertz, Morie A.
    Warsame, Rahma
    Muchtar, Eli
    Buadi, Frances
    Dispenzieri, Angela
    Gonsalves, Wilson
    Dingli, David
    Hayman, Suzanne
    Kapoor, Prashant
    Kourelis, Taxiarchis
    Kumar, Shaji K.
    Lacy, Martha Q.
    Hogan, William
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2422 - 2427
  • [26] A Retrospective Analysis of Transplant and Infectious Outcomes of a Temporal Break between Mobilization and Administration of Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant
    Barry, Austin
    Baljevic, Muhamed
    Holstein, Sarah A.
    Bociek, R. Gregory
    Shostrom, Valerie K.
    Schmit-Pokorny, Kim
    Vose, Julie M.
    Lunning, Matthew A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S257 - S257
  • [27] Pharmacokinetics of Melphalan in Lymphoma Patients undergoing Beam and Autologous Hematopoietic Stem Cell Transplant
    Dahi, Parastoo
    Lin, Andew
    Flynn, Jessica
    Uruburo, Christian
    Mcgeary, Ian
    Schofield, Ryan
    Bhatt, Valkal
    Derespiris, Lauren
    Figgins, Bradley
    Griffin, Meagan
    Lau, Carmen
    Proli, Anthony
    Carlow, Dean
    Cho, Christina
    Lahoud, Oscar
    Perales, Miguel
    Sauter, Craig
    Scordo, Michael
    Shah, Gunjan
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 285 - 286
  • [28] CAN OVERALL SURVIVAL BE IMPROVED IN ELDERLY MULTIPLE MYELOMA PATIENTS?
    Heeg, B. M.
    Liwing, J.
    Karstorp, S.
    Postma, M.
    Silvennoinen, R.
    Putkonen, M.
    Anttila, P.
    Remes, K.
    Abildgaard, N.
    Waage, A.
    Nahi, H.
    HAEMATOLOGICA, 2015, 100 : 517 - 517
  • [29] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
    Mateos, Maria-Victoria
    Cavo, Michele
    Blade, Joan
    Dimopoulos, Meletios A.
    Suzuki, Kenshi
    Jakubowiak, Andrzej
    Knop, Stefan
    Doyen, Chantal
    Lucio, Paulo
    Nagy, Zsolt
    Pour, Ludek
    Cook, Mark
    Grosicki, Sebastian
    Crepaldi, Andre H.
    Liberati, Anna Marina
    Campbell, Philip
    Shelekhova, Tatiana
    Yoon, Sung-Soo
    Iosava, Genadi
    Fujisaki, Tomoaki
    Garg, Mamta
    Krevvata, Maria
    Wang, Jianping
    Kudva, Anupa
    Ukropec, Jon
    Wroblewski, Susan
    Kobos, Rachel
    San-Miguel, Jesus
    BLOOD, 2019, 134
  • [30] The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
    Chang, H
    Sloan, S
    Li, D
    Zhuang, LH
    Yi, QL
    Chen, CI
    Reece, D
    Chun, K
    Stewart, AK
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) : 64 - 68